Is Mile High Compounds Legit? Reviews, Coupons & FDA

Short answer: they are a real company with genuinely happy customers, and we do not currently recommend them.

Mile High Compounds holds a 4.7 TrustScore across 429 Trustpilot reviews, 93% of them five-star. That is a good score and we are not going to pretend otherwise. Two things sit against it. The first is a pattern in the negative reviews that a star average hides. The second is an FDA warning letter, noted at the bottom of this page.

Disclosure: we previously had an affiliate relationship with Mile High Compounds. They closed our account in August 2026 citing a terms violation they never identified, and a balance of earned commission remains unpaid. We also earn commission from the vendors recommended below.

Research-context information only. Compounds discussed below are research peptides; some are investigational drugs not approved by the FDA. Protocols, doses, and reactions reported come from published research, regulatory filings, and self-reported community sources. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

Mile High Compounds coupon codes

If you came here for a discount code, the honest position is that we do not have one for Mile High. The code we used to publish was tied to our affiliate account, which is closed, so it no longer tracks or discounts anything.

These do work, and we check them against live vendor pricing every day:

Is Mile High Compounds legit?

They are a real, operating, US-based company. Orders ship, the storefront is genuine, and hundreds of customers report good experiences with fast delivery and responsive support. Nothing we found suggests otherwise.

"Legit" and "worth buying from" are different questions, though — and the second one is where the reviews get interesting.

What customers actually say

This is where a star average misleads, and the mechanism is worth understanding.

The aggregate is 4.7 across 429 reviews — 93% five-star, 1-star 3%, 2-star under 1%. Read that alone and there is no story here.

But "shipping was fast, the product did nothing" is a three-star review. It barely moves a 4.7. So we read every review in the 1-3 star bands and coded them by theme. The distribution is not random:

Seven separate reviewers report that the product did nothing, most naming retatrutide specifically, with dates running from December 2025 to July 2026.

The most useful of them is internally controlled. One reviewer reports that tirzepatide from this vendor worked while the retatrutide did not — same buyer, same supplier, same handling, different outcome by compound. Another reviewer writes that they self-administered retatrutide over five weeks, working up to a self-selected 2.5mg, and reported no change in appetite — then asked publicly whether anyone had had a vial independently tested. A third self-reports no effect after roughly 9mg cumulative. These are unverified customer accounts of their own use, not protocols and not measurements.

Two more reports bear on the same question from a different angle. One reviewer states that the batch numbers on the vials did not correspond with the supplied Certificates of Analysis. Another reports cloudy retatrutide and vials arriving without a vacuum seal, citing a specific batch number.

In fairness, the company replied to most of these — Trustpilot records responses to 81% of negative reviews. Those replies point to per-batch third-party testing, offer to investigate specific orders, attribute some dissolution complaints to the wrong reconstitution solvent, and in one case dispute that the reviewer was a recent customer at all. They are reasonable responses and worth weighing.

Two things we deliberately left out: one 1-star review on their page is about an infrared sauna and a finance dispute and has nothing to do with this company, and one long review makes personal claims about the founder that are not evidence of anything about the products.

What to take from it: the aggregate is good and most buyers are happy. But if you are buying retatrutide specifically, seven independent reports of no effect — alongside a COA traceability complaint — is a pattern worth knowing before you spend a few hundred dollars.

Our own experience

We listed Mile High as a recommended vendor in July 2026. A month later they closed our affiliate account, saying we had violated their terms by "bidding on words" — running paid search ads against their brand. We do not run paid search at all, for any vendor. We asked what specific conduct was at issue and got no answer. A balance of earned commission was outstanding when the account closed, and remains unpaid.

We also could not find an affiliate agreement to check ourselves against: their terms page covers customers only, and the page titled "Affiliate Program Terms" contains none.

That is a data point about how the company handles disputes, not a claim about their products. The product evidence is set out above and sourced, so the two can be weighed separately.

Where to buy instead

Match the alternative to what you came for:

Every compound Mile High carried is stocked by at least one vendor we track, and on most of them at a lower price. For live price-per-milligram across all of them, see the full price comparison.

Footnote: the FDA warning letter

Worth recording, but it matters less than the pattern above. Warning letters are a routine feature of this market — the FDA has issued them to a long list of research-compound sellers, and receiving one does not by itself separate a vendor from its competitors.

What is worth noting is that Mile High was named specifically, while most of the vendors they compete with were not. On 31 March 2026 the FDA's Center for Drug Evaluation and Research issued warning letter MARCS-CMS 721600, citing four products — GLP-1 SM, GLP-2 TRZ, GLP-3 RT and BAC Water — as "unapproved new drugs under section 505(a)" of the Federal Food, Drug, and Cosmetic Act.

The substantive finding is that the research-use labelling did not hold. Despite marketing the products for "in vitro research and educational purposes only," the agency wrote that "evidence obtained from your website establishes that your products are intended to be drugs for human use" — citing dosing instructions the company had published through its own community forum. The full letter is public on fda.gov.